plenti cmv blast dest addgene plasmid Search Results


plenti tetr blast mammalian expression plasmid  (Addgene inc)
93
Addgene inc plenti tetr blast mammalian expression plasmid
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Plenti Tetr Blast Mammalian Expression Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMV+TetR+Blast+(716-1)+(Plasmid+%2317492)/pmc08893345-130-0-7
Average 93 stars, based on 1 article reviews
plenti tetr blast mammalian expression plasmid - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
eric campeau  (Addgene inc)
94
Addgene inc eric campeau
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Eric Campeau, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMV+Blast+DEST+(706-1)+(Plasmid+%2317451)/pm38136319-37-26-31
Average 94 stars, based on 1 article reviews
eric campeau - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
plenti cmv blast empty w263 1  (Addgene inc)
94
Addgene inc plenti cmv blast empty w263 1
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Plenti Cmv Blast Empty W263 1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMV+Blast+empty+(w263-1)+(Plasmid+%2317486)/pmc11323225-836-11-16
Average 94 stars, based on 1 article reviews
plenti cmv blast empty w263 1 - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
pip fucci plasmid  (Addgene inc)
93
Addgene inc pip fucci plasmid
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Pip Fucci Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti-CMV-Blast-PIP-FUCCI+(Plasmid+%23138715)/pm38823395-1050-13-15
Average 93 stars, based on 1 article reviews
pip fucci plasmid - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
rtta3 lentiviral particles  (Addgene inc)
94
Addgene inc rtta3 lentiviral particles
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Rtta3 Lentiviral Particles, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMV+rtTA3+Blast+(w756-1)+(Plasmid+%2326429)/pm41832176-289-12-19
Average 94 stars, based on 1 article reviews
rtta3 lentiviral particles - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
lentivector plenti cmv blast dntgfbr2 ha  (Addgene inc)
93
Addgene inc lentivector plenti cmv blast dntgfbr2 ha
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Lentivector Plenti Cmv Blast Dntgfbr2 Ha, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti-CMV-Blast-DNTGFBR2-HA+(Plasmid+%23130888)/pmc12422981-252-8-15
Average 93 stars, based on 1 article reviews
lentivector plenti cmv blast dntgfbr2 ha - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
luciferase expressing plenti cmv v5 luc blast w567 1  (Addgene inc)
93
Addgene inc luciferase expressing plenti cmv v5 luc blast w567 1
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Luciferase Expressing Plenti Cmv V5 Luc Blast W567 1, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMV+V5-LUC+Blast+(w567-1)+(Plasmid+%2321474)/pm25219463-71-65-72
Average 93 stars, based on 1 article reviews
luciferase expressing plenti cmv v5 luc blast w567 1 - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
plenti pgk blast dest  (Addgene inc)
93
Addgene inc plenti pgk blast dest
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Plenti Pgk Blast Dest, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+PGK+Blast+DEST+(w524-1)+(Plasmid+%2319065)/pmc05641107-157-5-9
Average 93 stars, based on 1 article reviews
plenti pgk blast dest - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier
plenti cmv gfp blast  (Addgene inc)
94
Addgene inc plenti cmv gfp blast
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Plenti Cmv Gfp Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMV+GFP+Blast+(659-1)+(Plasmid+%2317445)/bio_rxiv__2025__06__08__658051-49-13-16
Average 94 stars, based on 1 article reviews
plenti cmv gfp blast - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier
plenti cmvtight blast dest  (Addgene inc)
92
Addgene inc plenti cmvtight blast dest
(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 <t>TetR</t> STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.
Plenti Cmvtight Blast Dest, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMVtight+Blast+DEST+(w762-1)+(Plasmid+%2326434)/pm27273514-595-48-55
Average 92 stars, based on 1 article reviews
plenti cmvtight blast dest - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier
g stearothermophilus  (Addgene inc)
92
Addgene inc g stearothermophilus

G Stearothermophilus, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+X2+Blast+DEST+(w46-2)+(Plasmid+%2317391)/pmc08370763-36-6-11
Average 92 stars, based on 1 article reviews
g stearothermophilus - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier
transactivator plenti cmvrtta3g blast  (Addgene inc)
92
Addgene inc transactivator plenti cmvrtta3g blast

Transactivator Plenti Cmvrtta3g Blast, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/plenti+cmv+blast+dest+addgene+plasmid/pLenti+CMV+rtTA3G+Blast+(R980-M38-658)+(Plasmid+%2331797)/pmc04964798-172-6-9
Average 92 stars, based on 1 article reviews
transactivator plenti cmvrtta3g blast - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

Image Search Results


(A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 TetR STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.

Journal: Cell reports

Article Title: Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells

doi: 10.1016/j.celrep.2021.110236

Figure Lengend Snippet: (A) STING transcript levels across TCGA tumor datasets relative to GTEx organ-matched normal tissues. (B) IHC analysis of STING expression in the UCLA PDAC tissue microarray (n = 138). (C) Immunoblot analysis of protein lysates prepared from STING WT and CRISPR-Cas9 KO HS766T or DANG subcutaneous xenograft tumors. (D) IncuCyte live-cell imaging analysis of SUIT2 TetR STINGR284M cells treated +50 ng/mL doxycycline (DOX) ± 500 nM VE-822 (ATR inhibitor [ATRi]) in anchorage-independent cultures (mean ± SD; n = 6; one-way ANOVA corrected for multiple comparisons by Bonferroni adjustment). Images are representative of respective experimental endpoints. (E) Immunoblot analysis of SUIT2 tumors from mice treated ± DOX diet ± AZD-6738 (25 mg/kg b.i.d.) for 3 days. (F) Experimental design to evaluate the impact of ATRi against PDAC tumors with active STING signaling. (G and H) NCG mice were inoculated with subcutaneous (s.c.; G; n = 8) or orthotopic (H; n = 4) SUIT2 TetR STINGR284M tumors. Mice were fed a DOX-supplemented diet starting 7 days after tumor inoculation and treated ±25 mg/kg ATRi AZD-6738 b.i.d. for 26 days (unpaired t test; mean ± SD). Tumor volumes were measured using micro-computed tomography (μCT). Mass of excised tumor tissue is indicated. *p < 0.05; ****p < 0.0001.

Article Snippet: pLENTI TetR BLAST mammalian expression plasmid , Addgene , Cat#17492.

Techniques: Expressing, Microarray, Western Blot, CRISPR, Live Cell Imaging, Micro-CT

KEY RESOURCES TABLE

Journal: Cell reports

Article Title: Reprogramming of nucleotide metabolism by interferon confers dependence on the replication stress response pathway in pancreatic cancer cells

doi: 10.1016/j.celrep.2021.110236

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: pLENTI TetR BLAST mammalian expression plasmid , Addgene , Cat#17492.

Techniques: Virus, Microarray, Recombinant, Lysis, Protease Inhibitor, Membrane, Saline, Autoradiography, Plasmid Preparation, Control, BIA-KA, Reverse Transcription, Enzyme-linked Immunosorbent Assay, Expressing, Software, Mass Spectrometry, Targeted Proteomics, Real-time Polymerase Chain Reaction, Live Cell Imaging

Journal: eLife

Article Title: McsB forms a gated kinase chamber to mark aberrant bacterial proteins for degradation

doi: 10.7554/eLife.63505

Figure Lengend Snippet:

Article Snippet: Recombinant DNA reagent , YwlE from G. stearothermophilus , , RRID: Addgene_173911 , pET-21a plasmid containing ywlE-His6 from G. stearothermophilus.

Techniques: Mutagenesis, Recombinant, Plasmid Preparation, Immunodepletion, Sequencing, Software